Key Highlights

  • InspireMD (NASDAQ:NSPR) was trading down 12.7% at USD 0.6757 in pre-market on Friday, November 13, 2026, implying a prior close of about USD 0.77 (calculated), after third-quarter results on November 12.
  • Third-quarter Revenue was USD 2.24 million, down 11.1% from USD 2.52 million, as US revenue fell to USD 32,000 from USD 497,000 after a May 2026 voluntary recall.
  • Gross Margin dropped to 10.7% from 34.2%, and the net loss was USD 9.76 million, or USD 0.12 a share, against USD 0.17 a share a year earlier.
  • Cash, equivalents and marketable securities were USD 19.2 million at September 30, 2026, down from USD 54.2 million at December 31, 2025, a fall of USD 35.0 million (calculated).

Q3 Revenue Falls as the CGuard Prime Recall Bites

InspireMD (NASDAQ:NSPR), a medical device maker behind the CGuard carotid stent platform, reported third-quarter 2026 results on November 12, 2026 after pushing back the original timing. Revenue was USD 2.24 million, down 11.1%. International revenue rose 9.1% to USD 2.21 million, but US revenue almost vanished, falling to USD 32,000 from USD 497,000. The company attributes that to a voluntary recall of the CGuard Prime for CAS delivery system in May 2026. Gross margin of 10.7% reflected the US shortfall and a mix shift toward lower-priced international markets.

Losses Narrow but Cash Has Fallen by Two Thirds

Operating expenses fell 26.7% to USD 10.19 million, including USD 1.07 million of restructuring costs, so the net loss per share improved to USD 0.12. The Balance Sheet is the weaker point: cash, equivalents and marketable securities of USD 19.2 million compare with USD 54.2 million at the end of 2025. The release does not give formal financial guidance, and its risk language cites substantial doubt about the company's ability to continue as a going concern, along with recall-related costs and liquidity. The pre-market price also compares with a published preview before the report that had shares near USD 0.66, about 22.6% lower since the prior report and under the 200-day average of USD 1.06.

FDA Approval for TCAR and the Timeline to a CAS Relaunch

There are positive items. The FDA approved CGuard Prime for TCAR procedures, which the company says roughly doubles its US addressable market, supported by the CGUARDIANS II pivotal trial that reported 100% acute device success. US sales for TCAR are expected to begin in the fourth quarter of 2026. A PMA supplement for the enhanced CGuard Prime for CAS is expected to be filed in December 2026, with a possible relaunch in the first half of 2027. Delays, further recall costs or financing at low prices would weigh on that plan, and the company has not given formal financial guidance for 2026 or 2027. Low-priced shares can swing widely on few trades, so the pre-market move is the figure of record for pre-market only.

Where Things Stand

A recovery is possible but unproven. The 12.7% pre-market drop follows a quarter with lower revenue, a thin gross margin and a US Business hit by a recall. InspireMD (NASDAQ:NSPR) does have a TCAR approval, a US launch expected in the fourth quarter and a December filing planned for the CAS system, but cash has fallen and the filing language mentions going-concern doubt. The next markers are the TCAR launch, the December 2026 PMA supplement and the next cash update.